Q-omics provides the consensus-scored ANKRD18CP profile across patient tissues and cancer cell-line models. ANKRD18CP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ANKRD18CP is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, ANKRD18CP RNA expression shows 16,975 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRP as cancer lineages where ANKRD18CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD18CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD18CP survival associations across molecular data types. ANKRD18CP RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD18CP RNA expression–survival associations across cancer types. High ANKRD18CP expression shows unfavorable associations in UVM, ACC, THCA, DLBC and KICH, but favorable associations in SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ANKRD18CP RNA expression.
This table summarizes ANKRD18CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD18CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD18CP shows lower tumor expression in THCA, KICH and ESCA and higher tumor expression in KIRP, LIHC and COAD. The KIRP box plot shows higher ANKRD18CP RNA expression in tumor versus normal tissue (log2 FC = +0.319, t-test p = .001).
This table shows molecular features associated with ANKRD18CP in patient tissues and cancer cell lines. In patient samples, ANKRD18CP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
